339 related articles for article (PubMed ID: 31074301)
1. Ivabradine for treatment of heart failure.
Bocchi EA; Salemi VMC
Expert Opin Drug Saf; 2019 May; 18(5):393-402. PubMed ID: 31074301
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study.
Tsutsui H; Momomura SI; Yamashina A; Shimokawa H; Kihara Y; Saito Y; Hagiwara N; Ito H; Yano M; Yamamoto K; Ako J; Inomata T; Sakata Y; Tanaka T; Kawasaki Y;
Circ J; 2019 Sep; 83(10):2049-2060. PubMed ID: 31391387
[TBL] [Abstract][Full Text] [Related]
3. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.
Bocchi EA; Rassi S; Guimarães GV;
ESC Heart Fail; 2018 Jun; 5(3):249-256. PubMed ID: 29266804
[TBL] [Abstract][Full Text] [Related]
4. Ivabradine: Current and Future Treatment of Heart Failure.
Thorup L; Simonsen U; Grimm D; Hedegaard ER
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
[TBL] [Abstract][Full Text] [Related]
6. Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction.
Tóth N; Soós A; Váradi A; Hegyi P; Tinusz B; Vágvölgyi A; Orosz A; Solymár M; Polyák A; Varró A; Farkas AS; Nagy N
Can J Physiol Pharmacol; 2021 Nov; 99(11):1159-1174. PubMed ID: 34636643
[TBL] [Abstract][Full Text] [Related]
7. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
Böhm M; Komajda M; Borer JS; Ford I; Maack C; Tavazzi L; Moyne A; Swedberg K;
Eur J Heart Fail; 2018 Feb; 20(2):373-381. PubMed ID: 29027329
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of heart failure treated with digoxin or with ivabradine: A cohort study in the community.
Guzman M; Gomez R; Romero SP; Aranda R; Andrey JL; Pedrosa MJ; Egido J; Gomez F
Int J Clin Pract; 2018 Nov; 72(11):e13217. PubMed ID: 30248211
[TBL] [Abstract][Full Text] [Related]
9. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials.
Bryan Richard S; Huang B; Liu G; Yang Y; Luo S
Clin Cardiol; 2021 Apr; 44(4):463-471. PubMed ID: 33638556
[TBL] [Abstract][Full Text] [Related]
10. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
Böhm M; Abdin A; Slawik J; Mahfoud F; Borer J; Ford I; Swedberg K; Tavazzi L; Batailler C; Komajda M
Eur J Heart Fail; 2023 Aug; 25(8):1429-1435. PubMed ID: 37092340
[TBL] [Abstract][Full Text] [Related]
11. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
Bouabdallaoui N; O'Meara E; Bernier V; Komajda M; Swedberg K; Tavazzi L; Borer JS; Bohm M; Ford I; Tardif JC
ESC Heart Fail; 2019 Dec; 6(6):1199-1207. PubMed ID: 31591826
[TBL] [Abstract][Full Text] [Related]
13. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
[TBL] [Abstract][Full Text] [Related]
14. Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a.
Shao S; Zhang Y; Gong M; Yang Q; Yuan M; Yuan M; Suo Y; Wang X; Li Y; Bao Q; Li G
Oxid Med Cell Longev; 2021; 2021():1257283. PubMed ID: 34630844
[TBL] [Abstract][Full Text] [Related]
15. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
Hidalgo FJ; Anguita M; Castillo JC; Rodríguez S; Pardo L; Durán E; Sánchez JJ; Ferreiro C; Pan M; Mesa D; Delgado M; Ruiz M
Int J Cardiol; 2016 Aug; 217():7-11. PubMed ID: 27167103
[TBL] [Abstract][Full Text] [Related]
16. The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure.
Ozturk S; Öztürk S; Erdem FH; Erdem A; Ayhan S; Dönmez İ; Yazıcı M
J Interv Card Electrophysiol; 2016 Sep; 46(3):253-8. PubMed ID: 27039084
[TBL] [Abstract][Full Text] [Related]
17. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
18. Update on ivabradine for heart failure.
Borer JS; Tavazzi L
Trends Cardiovasc Med; 2016 Jul; 26(5):444-9. PubMed ID: 26934996
[TBL] [Abstract][Full Text] [Related]
19. The role of heart rate and ivabradine in acute heart failure.
Sciatti E; Vizzardi E; Bonadei I; Dallapellegrina L; Carubelli V
Monaldi Arch Chest Dis; 2019 Oct; 89(3):. PubMed ID: 31594282
[TBL] [Abstract][Full Text] [Related]
20. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
